Lora Grassilli News Today

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in...

$95 million in development milestones payable over two years, as part of GSK license agreement...

CAMBRIDGE, Mass., Jan. 02, 2024 -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high...

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas

Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET...

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and...

Phase3PIVOT-POtrialisexpectedtobeginwithFirstPatient,FirstVisitin4Q2023

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr... | May 11, 2023

/PRNewswire/ -- Danone North America, today announced alongside its Specialized Nutrition business, Nutricia, the availability of Pepticate in the U.S. to help...